BSF Enterprise (LSE:BSFA), the London-listed life sciences group developing cultivated leather and tissue-engineering technologies, announced it is extending its platform into humanoid robotics, filing a UK patent application for a tissue-based covering designed to solve seam and sensor problems in robotic hands.
The subsidiary behind the filing, 3D Bio-Tissues, has lodged a priority application with the UK Intellectual Property Office titled "Tissue Assembly Method and/or Tissue Assembly", with a priority date of 28 September.
The same monolithic, stitchless 3D tissue-assembly technology already underpins Lab-Grown Leather's Elemental Lux material, currently in partner-funded commercial evaluation with two global luxury fashion houses as it moves toward large-format sheet testing in the first half of 2027.
BSF frames the robotics move as solving a mechanical bottleneck facing humanoid platforms as they shift from prototypes to fleet deployment: conventional silicone or glued elastomer coverings suffer seam failure under friction, restrict joint movement and dampen tactile and thermal sensor signals.
The patent application describes a single continuous moulded piece of variable thickness, wear-resistant over contact pads but as thin as 0.3mm over articulating joints, formed from native collagen that the company says transmits contact forces to underlying sensors without the stiffness of synthetic rubber.
The material is processed at ambient physiological temperatures below 40°C, avoiding the high-temperature vulcanisation cycles synthetic elastomers require.
The foundational technology traces back to 3D Bio-Tissues' proprietary macromolecular crowding media, which received a USPTO Notice of Allowance across 17 claims covering scalable skin, corneal and extracellular matrix production.
BSF intends to commercialise the robotics application through joint development agreements with tier-one robotics manufacturers and automation developers, who would fund application-specific tooling, sensor integration and durability testing, while 3D Bio-Tissues retains full ownership of its underlying synthesis IP, cell lines and media formulations including CityMix and CytoBoost.
"The exact same monolithic, stitchless 3D tissue architecture that we are currently executing under funded commercial programmes with global luxury fashion houses via Lab-Grown Leather translates directly into solving the most demanding component challenge in modern humanoid robotics," said Che Connon, chief executive of BSF Enterprise.
He added that the group would "execute this vertical via partner-funded development agreements, securing long-term high-margin component supply while protecting our group cash runway."